BLU 285 companion diagnostic - Blueprint Medicines/QIAGEN

Drug Profile

BLU 285 companion diagnostic - Blueprint Medicines/QIAGEN

Alternative Names: BLU-285 companion diagnostic - Blueprint Medicines/QIAGEN

Latest Information Update: 17 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Blueprint Medicines; QIAGEN
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Gastrointestinal stromal tumours

Most Recent Events

  • 22 Aug 2016 Blueprint Medicines and QIAGEN agree to co-develop and co-promote BLU 285 companion diagnostic in countries worldwide, primarily USA, European Union and Canada for Gastrointestinal stromal tumor (Diagnosis) (Blueprint Medicines Form 8-K, August 2016),
  • 22 Aug 2016 Early research in Gastrointestinal stromal tumours (Diagnosis) in Germany and USA (unspecified route) (Blueprint Medicines Form 8-K, August 2016),
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top